| Aldosterone receptor antagonists: focus on eplerenone. | |
| | |
MedLine Citation:
|
PMID: 12624573 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite the development of hypertension treatment guidelines, blood pressure control in the general population remains inadequate, indicating the need for ongoing re-evaluation of treatment strategies to further improve blood pressure control. Hypertension results from alterations in cardiac output and/or peripheral resistance. The renin-angiotensin-aldosterone system may be responsible, at least in part, for these alterations. Despite pharmacologic intervention with angiotensin-converting enzyme inhibitors and angiotensin type-1 receptor antagonists, aldosterone continues to be produced. Therapeutic modalities for treating hypertension directed toward antagonizing aldosterone might more effectively control blood pressure. Eplerenone, a new selective aldosterone receptor antagonist, recently received approval from the US Food and Drug Administration for the treatment of hypertension, either alone or in combination with other antihypertensive agents. The objective of this review is to summarize the renin-angiotensin-aldosterone system, emphasizing the role for aldosterone antagonism in the management of hypertension, with a focus on eplerenone. |
| | |
Authors:
|
Robert E Lamb; Jon Folstad |
Related Documents
:
|
7721433 - Lead increases aldosterone production by rat adrenal cells. 2180043 - Aldosterone-producing tumors (conn's syndrome). 21547173 - Respiratory changes during spinal anaesthesia for gynaecological laparoscopic surgery. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Progress in cardiovascular nursing Volume: 18 ISSN: 0889-7204 ISO Abbreviation: Prog Cardiovasc Nurs Publication Date: 2003 |
Date Detail:
|
Created Date: 2003-03-07 Completed Date: 2003-05-15 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 8704064 Medline TA: Prog Cardiovasc Nurs Country: United States |
Other Details:
|
Languages: eng Pagination: 54-9 Citation Subset: IM; N |
Copyright Information:
|
Copyright 2003 CHF, Inc. |
Affiliation:
|
AstraZeneca LP, 725 Chesterbrook Boulevard, Wayne, PA 19087, USA. robert.lamb@astrazeneca.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone Antagonists
/
standards,
therapeutic use Antihypertensive Agents / antagonists & inhibitors, standards, therapeutic use Blood Pressure / drug effects Cardiac Output / drug effects Humans Receptors, Aldosterone / antagonists & inhibitors*, therapeutic use Renin-Angiotensin System / drug effects Spironolactone / analogs & derivatives*, antagonists & inhibitors, standards, therapeutic use United States Vascular Resistance / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Antihypertensive Agents; 0/Receptors, Aldosterone; 0/eplerenone; 52-01-7/Spironolactone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiovascular nursing in Israel.
Next Document: Clinical correlates of isolated left ventricular diastolic dysfunction among hospitalized older hear...